KNSA Kiniksa Pharmaceuticals Ltd: Price-to-Projected Revenue Ratio

Public company logo of Kiniksa Pharmaceuticals (KNSA)

The strategic goal of Kiniksa Pharmaceuticals (KNSA) is to dominate the treatment of recurrent pericarditis through its monopoly drug ARCALYST. The forward price-to-sales ratio on the GURU.Markets chart illustrates the path toward this objective, where 5.60 represents the current level of the metric. High pricing for orphan therapy and patent protection create market barriers, while growth relies solely on the licensing of new molecules.

Kiniksa - KNSA Market Cap to Expected Sales Ratio (period 07/04/2022 - 11/16/2026)

Analytical breakdowns for Kiniksa Pharmaceuticals

- current price and projected stock value:
- company stock capitalization data:
Fundamental company analysis:KNSA (Kiniksa Corp)
Product sample of Kiniksa Pharmaceuticals

Forward P/S assesses the market value of a business relative to expected revenue, allowing an investor to determine the extent of overpayment for future cash flows amid volatility. By analyzing the projected P/S ratio, one can evaluate whether the antibody patent protection of Kiniksa Pharmaceuticals (KNSA) and its monopoly status in biotechnology justify the current capitalization, confirming the company's fundamental stability.

Analysis of competing companies

Forward P/S Multiple ARGX (argenx.com)|BioNTech Group (BNTX) - Market Cap to Future Revenue Ratio|ABIVAX - Forward P/S Multiple|ADMA - Forward P/S Multiple|Protagonist (PTGX) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Immunovant Inc|GRFS (Grifols Biemat) - Forward P/S Multiple|Forward P/S Multiple Adaptive Biotechnologies Inc.|Price-to-Projected Revenue Ratio Celldex Therapeutics (CLDX)|Market Cap to Expected Sales Ratio auriniapharma.com|Price-to-Projected Revenue Ratio BioCryst Pharmaceuticals BCRX|Forward Price to Sales VERA|Dianthus Pharma - Forward P/S Multiple|PHVS - Forward P/S Multiple|ABCL: Forward P/S Multiple|TRML (Tourmaline Bio, Inc.) - Price-to-Projected Revenue Ratio|Price-to-Projected Revenue Ratio Intrexon|PHAR - Projected Price to Revenue|Forward P/S Multiple NKTR|Price-to-Projected Revenue Ratio UPB (Upstream Bio Corp)|Price-to-Projected Revenue Ratio Zenas Biopharma, Inc. ZBIO|Market Cap to Expected Sales Ratio immunome.com (IMNM)|Gossamer Bio Inc - Forward P/S Multiple|Forward Price to Sales KALV (KalVista Pharmaceuticals, Inc.)|SEPN: Forward P/S Multiple|Forward Price-to-Revenue Multiple Pieris Pharmaceuticals Inc|Forward Price-to-Revenue Multiple SVRA|Forward Price-to-Revenue Multiple Rigel Pharmaceuticals (RIGL)|Forward P/S Multiple ANAB|ATXS - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio enGene Corp ENGN|Market Cap to Expected Sales Ratio RAPT Therapeutics, Inc. (RAPT)|Aerovate - Forward P/S Multiple|ACRS - Forward P/S Multiple|KYTX (Kyverna Therapeutics) - Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio Tiziana Life Sciences Ltd. (TLSA)|Forward Price-to-Revenue Multiple CABA|Ventyx Biosciences (VTYX) - Market Cap to Expected Sales Ratio|Forward P/S Multiple THTX|AVTX (Avalo Therapeutics, Inc) - Forward Price to Sales|Forward P/S Multiple ELDN (eledon.com)|AGEN - Forward Price-to-Revenue Multiple|CLYM - Price-to-Projected Revenue Ratio|Future Price to Revenue ZURA|ATYR: Forward P/S Multiple|Adagene Corp (ADAG) - Forward P/S Multiple|Forward Price-to-Revenue Multiple IMA|Shattuck Labs, Inc. - Future Price to Revenue|Price-to-Projected Revenue Ratio Equillium Inc (EQ)|Forward P/S Multiple Connect Biopharma Holdings (CNTB)|Price-to-Projected Revenue Ratio Immunic, Inc. IMUX|Forward P/S Multiple Atara Biotherapeutics ATRA|IFRX - Price-to-Projected Revenue Ratio|XFOR: Price-to-Projected Revenue Ratio|ACET: Forward P/S Multiple|CELU - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio inmunebio.com|Market Cap to Projected Revenue BRNS (barinthusbio.com)|Forward P/S Multiple KZR|Forward P/S Multiple SAB Biotherapeutics, Inc (SABS)|Forward P/S Multiple AKTX (Akari Therapeutics, Plc)|Forward P/S Multiple enlivex.com ENLV|QTTB: Forward Price-to-Revenue Multiple|GOVX - Forward P/S Multiple|Edesa Biotech Inc (EDSA) - Price-to-Projected Revenue Ratio|IBIO - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio carismatx.com|XTLB: Forward Price to Sales|Price-to-Projected Revenue Ratio Bolt Biotherapeutics Inc. (BOLT)|HCW Biologics - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio aptevotherapeutics.com APVO|AIM - Forward Price-to-Revenue Multiple|Aditxt - Forward P/S Multiple|Market Cap to Expected Sales Ratio GRI Bio Corporation GRI|xortx.com (XRTX) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio reshapelifesciences.com (HIND)|Price-to-Projected Revenue Ratio Revelation Bio|Market Cap to Future Revenue Ratio Indaptus Therapeutics, Inc. INDP|Price-to-Projected Revenue Ratio BiondVax Pharmaceuticals (SCNI)|Forward Price-to-Revenue Multiple CalciMedica CALI|Price-to-Projected Revenue Ratio Affimed AFMD|ALLK - Forward Price-to-Revenue Multiple|HOOKIPA Pharma, Inc. - Forward P/S Multiple|Forward Price to Sales IGMS (igmbio.com)|ITOS (iTeos Therapeutics, Inc.) - Forward Price-to-Revenue Multiple|Ocean Biomedical Corp (OCEA) - Forward P/S Multiple|Price-to-Projected Revenue Ratio TC BioPharm (Holdings) PLC|Forward P/S Multiple thirdharmonicbio.com